Val-Cit-amide-Cbz-N(Me)-Maytansine

• CAT Number: I040529
• CAS Number: 1628543-59-8
• Molecular Formula: C55H78ClN9O15
• Molecular Weight: 1140.71
• Purity: ≥95%
• Synonyms: [(1S,2R,3S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl] (2S)-2-[3-[[4-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-5-(carbamoylamino)pentanoyl]amino]phenyl]methoxycarbonyl-methylamino]propanoyl-methylamino]propanoate
• IUPAC Name: [(1S,2R,3S,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl] (2S)-2-[3-[[4-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-5-(carbamoylamino)pentanoyl]amino]phenyl]methoxycarbonyl-methylamino]propanoyl-methylamino]propanoate
• InChI: InChI=1S/C55H78ClN9O15/c1-30(2)46(57)49(69)61-37(15-13-22-59-51(58)71)48(68)60-36-19-17-34(18-20-36)29-77-53(73)63(7)23-21-43(66)64(8)33(5)50(70)79-42-27-44(67)65(9)38-25-35(26-39(75-10)45(38)56)24-31(3)14-12-16-41(76-11)55(74)28-40(78-52(72)62-55)32(4)47-54(42,6)80-47/h12,14,16-20,25-26,30,32-33,37,40-42,46-47,74H,13,15,21-24,27-29,57H2,1-11H3,(H,60,68)(H,61,69)(H,62,72)(H3,58,59,71)/b16-12+,31-14+/t32-,33+,37+,40+,41-,42+,46+,47+,54?,55+/m1/s1
• InChIKey: WHRVZTYLCHEVBV-IRINPGTESA-N
• SMILES: CC1C2CC(C(C=CC=C(CC3=CC(=C(C(=C3)OC)Cl)N(C(=O)CC(C4(C1O4)C)OC(=O)C(C)N(C)C(=O)CCN(C)C(=O)OCC5=CC=C(C=C5)NC(=O)C(CCCNC(=O)N)NC(=O)C(C(C)C)N)C)C)OC)(NC(=O)O2)O

Val-Cit-amide-Cbz-N(Me)-Maytansine(CAT: I040529) is a synthetic maytansinoid derivative featuring a cleavable dipeptide linker (Valine-Citrulline) and a carbobenzoxy (Cbz) protected N-methyl group, engineered for targeted drug delivery applications. This construct is commonly used in the development of antibody-drug conjugates (ADCs), where the Val-Cit linker enables selective intracellular drug release upon proteolytic cleavage in the lysosome. The maytansine core, a potent microtubule inhibitor, delivers strong cytotoxic activity against dividing cancer cells. Val-Cit-amide-Cbz-N(Me)-Maytansine is ideal for oncology research, cytotoxic payload optimization, and ADC efficacy evaluation in vitro and in vivo. Provided at high purity for advanced preclinical and pharmaceutical research use.